An international study, published in the European Respiratory Journal, has indicated massive discrepancies in patient access to the most effective lung cancer testing and treatment. The study was the first of its kind to look at the worldwide availability of epidermal growth factor receptor (EGFR) tests and the subsequent effect on patients' access to tyrosine kinase inhibitors (TKIs), an essential alternative to chemotherapy in certain areas.
Read the ERJ article.
No comments:
Post a Comment